Immunotherapy to become standard treatment for infants with ALL
European Pharmaceutical Review
APRIL 27, 2023
Blinatumomab significantly improved survival, with the rate increasing from 66 percent to 93 percent, compared to individuals just given prior chemotherapy. Monoclonal antibody ( mAb ) blinatumomab binds to leukaemia cells on one side and to immune cells on the other side.
Let's personalize your content